LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

Search

Bristol-Myers Squibb Co.

Fermé

SecteurSoins de santé

60 1.9

Résumé

Variation du prix de l'action

24h

Actuel

Min

58.26

Max

60.01

Chiffres clés

By Trading Economics

Revenu

-1.1B

76M

Ventes

442M

12B

P/E

Moyenne du Secteur

14.05

73.239

BPA

1.67

Rendement du dividende

4.06

Marge bénéficiaire

0.616

Employés

34,100

EBITDA

-1.9B

2.6B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+3.45% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.06%

3.06%

Prochains Résultats

24 avr. 2025

Date du Prochain Dividende

1 mai 2025

Date du Prochain Détachement de Dividende

4 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-744M

120B

Ouverture précédente

58.1

Clôture précédente

60

Sentiment de l'Actualité

By Acuity

35%

65%

120 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Bristol-Myers Squibb Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mars 2025, 10:13 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mars 2025, 10:13 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 févr. 2025, 12:13 UTC

Résultats

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 mars 2025, 09:30 UTC

Actualités

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 mars 2025, 02:26 UTC

Acquisitions, Fusions, Rachats

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 mars 2025, 02:26 UTC

Acquisitions, Fusions, Rachats

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 mars 2025, 02:26 UTC

Acquisitions, Fusions, Rachats

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 mars 2025, 02:23 UTC

Acquisitions, Fusions, Rachats

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 mars 2025, 02:22 UTC

Acquisitions, Fusions, Rachats

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 mars 2025, 02:21 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 mars 2025, 02:21 UTC

Acquisitions, Fusions, Rachats

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 mars 2025, 02:19 UTC

Acquisitions, Fusions, Rachats

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 févr. 2025, 15:35 UTC

Résultats

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 févr. 2025, 13:56 UTC

Résultats

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 févr. 2025, 13:25 UTC

Actualités
Résultats

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 févr. 2025, 12:00 UTC

Résultats

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 févr. 2025, 11:59 UTC

Résultats

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol-Myers Squibb 4Q Net $72M >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 févr. 2025, 11:59 UTC

Résultats

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Comparaison

Variation de prix

Bristol-Myers Squibb Co. prévision

Objectif de Prix

By TipRanks

3.45% hausse

Prévisions sur 12 Mois

Moyen 60.93 USD  3.45%

Haut 70 USD

Bas 37 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

16 ratings

5

Achat

10

Maintien

1

Vente

Score Technique

By Trading Central

59.535 / 60.13Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

120 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.